Esketamine Nasal Spray

Beskrivelse

Esketamine Neusspray is the nasal spray formulation of esketamine, the S-enantiomer of ketamine. It is approved for use in adults with treatment-resistant depression (TRD) — depression that has not responded adequately to at least two different antidepressants — and for major depressive disorder (MDD) with acute suicidal thoughts or behavior, in combination with an oral antidepressant.

How Esketamine Neusspray Works Esketamine acts as a non-competitive NMDA receptor antagonist. By blocking NMDA receptors, it rapidly increases glutamate release, stimulates AMPA receptors, and promotes the restoration of synaptic connections in brain areas involved in mood regulation. This mechanism provides fast-acting relief, often within 2–24 hours, unlike conventional antidepressants that can take weeks.

Main Uses:

• Treatment-resistant depression (TRD)
• Major depressive disorder with suicidal ideation/behavior
• Used together with an oral antidepressant for enhanced effect

Dosage and Administration Esketamine nasal spray is self-administered under the supervision of a healthcare provider in a certified medical setting. The typical induction phase involves twice-weekly dosing (56mg or 84mg per session), followed by a maintenance phase of once-weekly or once every two weeks. Each device delivers 28mg (two sprays per nostril). Patients must be monitored for at least 2 hours after administration for side effects such as dissociation, sedation, or increased blood pressure.

Quality and Formulation Esketamine Neusspray comes in single-use nasal spray devices. The original brand is Spravato by Janssen (Johnson & Johnson). Generic versions may be available in some markets. Manufactured under strict GMP standards with precise dosing control.

Warnings and Precautions Esketamine is a Schedule III controlled substance with potential for misuse, dependence, and abuse. Common side effects include dissociation (feeling detached from reality), dizziness, sedation, vertigo, increased blood pressure, nausea, and changes in taste. Due to these risks, it cannot be taken home and must be administered in a healthcare facility with post-dose monitoring.

Contraindicated in patients with aneurysmal vascular disease, arteriovenous malformation, or recent intracerebral hemorrhage. Caution in patients with hypertension, psychiatric disorders, or history of substance abuse. Not recommended during pregnancy or breastfeeding. Patients must not drive or operate machinery for the rest of the day after treatment.

Esketamine Neusspray offers new hope for patients with hard-to-treat depression when used as part of a comprehensive treatment plan under specialist psychiatric supervision.